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Abstract
Background: Brain cancer is a rare and deadly malignancy with a low survival rate. The present study aims to evaluate
the epidemiology of brain cancer and its relationship with the human development index (HDI) worldwide.
Methods: This is an ecological study. The data on cancer incidence and cancer mortality was extracted from the World
Bank for Cancer in 2018 (GLOBOCAN 2018). The incidence, mortality rate, and brain cancer distribution maps were
drawn for different countries. We used correlation and regression tests to examine the association of incidence and
mortality rates of brain cancer with HDI. The statistical analysis was carried out by Stata-14 and a significance level of
0.05 was considered.
Results: According to the results of Global Cancer Registry in 2018, there were 18,078,957 registered cases of cancer in
both sexes, of which 29,681 were related to brain cancer. The highest incidence (102,260 cases, 34.4%) and mortality
(77,815 cases, 32.3%) belonged to very high HDI regions. Results showed that incidence (r = 0.690, P < 0.0001) and
mortality rates (r = 0.629, P < 0.001) of brain cancer are significantly correlated with HDI. We also observed a positive
correlation between brain cancer incidence and Gross National Income (GNI) (r = 0.346, P < 0.001), Mean Years of
Schooling (MYS) (r = 0.64, P < 0.001), TABLE (LEB) (r = 0.66, P < 0.001) and Expected Years of Schooling (EYS) (r = 0.667,
P < 0.001). Results also revealed that mortality rate was significantly correlated with GNI (r = 0.28, P < 0.01), MYS (r =
0.591, P < 0.01), LEB (r = 0.624, P < 0.01), and EYS (r = 0.605, P < 0.01).
Conclusion: The results of the study showed that the incidence and mortality of brain cancer in countries with higher
HDI levels is higher than countries with lower HDI levels, so attention to risk factors and action to reduce it in countries
with higher HDI levels in controlling this cancer in this Countries are effective.
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Background
Today, non-communicable diseases (NCDs) are a lead-
ing cause of death worldwide [1]. According to WHO
estimates, cancer was the first or second leading cause of
mortality in people before under 70 years of age in most
countries worldwide in 2015 [2]. Population growth,
population aging and economic development are the
main reasons for rising prevalence of cancer worldwide
[3, 4]. Cancers are the leading cause of death in some
developed countries and the second major cause of death
after cardiovascular disease in developing countries [5].
Brain cancer is a major cancer whose prevalence has been
on rise in recent decades [6]. Malignant brain tumors are
relatively rare, accounting for only 1–2% of all types of can-
cer in adults [7]. According to GLOBOCAN 2012, brain
cancer is one of rare types of cancers around the world.
Considering the low survival of patients with brain cancer
and its impact on patients’ quality of life, economic costs,
and mortality rate, it demands special attention [6, 8].
The main factors in the development of brain cancer
are exposure to ionizing radiation, pesticides, and cyclic
aromatic hydrocarbons [9]. Environmental and socioeco-
nomic factors influence mortality induced by brain cancer
[10–14]. The discrepancy in brain cancer incidence around
the world is due to factors such as causative factors,
improved diagnostic methods and enhanced medical care
in different countries [15].
There is tremendous variation in the detection rate of
brain cancer’s new cases worldwide [16]. The global
demographic and epidemiological trends indicate a
dramatic increase in cancers over the coming decades,
especially in low- and middle-income countries [17].
The incidence of brain tumors is higher in the Western
countries than in the Eastern countries. It is also higher
in developed countries than in developing countries.
The highest incidence of brain tumor has been observed
in Australia, North America and Northern Europe and
the lowest incidence in Africa [18].
According to the latest report from the National Vital
Statistics System for the period of 1975 to 2016, the
mortality rate has been higher among men and old
people [19]. The incidence of brain cancer in developed
countries is higher than in developing countries [18].
However, the highest rate of age-specific mortality of
brain cancer can be found in developing countries [20].
The burden of brain cancer is also higher in areas with
high HDI, according to a 1990 United Nations’ estimate
of the Human Development Index (HDI). As a summary
of human development system, HDI measures the basic
dimensions of human development including a long and
healthy life, education, and decent standards of living [21].
Given the global pattern of brain cancer and its timing
in recent years, it is essential to raise public awareness
about this cancer with the goal of planning and management
of financial and human resources to prevent this cancer. Des-
pite the growing burden of cancers in developing countries,
they account only for 5% of global spending on cancers [22].
Each country is required to assess whether socioeconomic
status has a bearing on cancer risk factors by comparing its
data with that of other countries.
The goal of this study is to examine the impact of so-
cioeconomic development (in terms of HDI) on global
trends in the incidence and mortality of brain cancer
worldwide based on data extracted from World Bank in
2018.
Methods
Given the limited quality and coverage of existing cancer
data in the world, especially in low-income or middle-
income countries, it is necessary to be cautious in inter-
preting these data. The International Agency for Research
on Cancer (IARC) approach is not just to evaluate, com-
pile and use data from other institutions, but the intention
of the centre is to work with country centres to improve
the quality of native data, data coverage and analytical
capacities. The urgent need for investing in the coverage
of cancer-based population data in low-.and middle-
income countries was to launch the Global Initiative for
the Cancer Registry Development (GICR) in cooperation
with the IARC. The GICR aims to provide information on
cancer control, which can be regularly promoted through
coverage, quality and use of population-based cancer data.
A summary of the steps used to calculate the incidence of
cancer, its mortality and its prevalence are presented
below. The calculation methods vary from country to
country, and the quality of the national computing data
depends on the coverage, accuracy, time of the outbreak
and the deaths at each country [5, 23].
Incidence
In this ecological study, age and gender-related incidence
rates in each country were calculated using the following
steps: 1. the nationally monitored incidence rate reported
by 45 countries until 2018; 2. The most recently observed
national or regional incidence rates for the population of 50
countries in 2018; 3. The rates calculated from modeling
national mortality data as well as mortality-to-incidence
ratio obtained from the cancer registry of countries
(14 countries); 4. The rates obtained from the estimates of
national mortality using mortality-to-incidence ratios derived
from cancer registries of neighboring countries (n= 37); 5.
National incidence rates of all types of cancer with respect to
gender and age obtained from calculating the average inci-
dence rates in neighboring countries. The obtained values
are then partitioned to achieve the national incidence rate for
each specific site using relative cancer incidence data
(7 countries), and 6. The rates calculated as the average
rates of incidence in selected neighboring countries.
Khazaei et al. BMC Public Health         (2020) 20:1696 Page 2 of 7
Mortality
The age and gender-related cancer mortality rates in
each country were calculated using the following steps:
1. Supervised national mortality rates reported in 81
countries) by 2018; 2. The most recent national mortal-
ity rates observed in 2018 used for the population of 20
countries; 3. Using relational modeling, mortality-to-
incidence rates and mortality rates collected from cancer
registry data in neighboring countries (n = 81); 4. The
mortality rates calculated as the averages of mortality
rate n selected neighboring countries (n = 3, [24, 25]).
HDI
HDI comprises three dimensions of education, life ex-
pectancy and decent standards of living. The regions and
countries with significant progress in all components of
HDI have a faster and higher growth than countries with
low or moderate HDI. According to this index, the
world is unequal since the national averages do not
reflect experiences of different individuals. There are
huge inequalities in the North and South, with the intra-
and inter-country inequality in income riding [26–28].
Results
According to the results of 2018 Cancer Registry, there
are 18,078,957 registered cases of cancers in both sexes,
of which 296,851 are related to brain cancers. The high-
est incidence of brain cancer was reported in Asia (156,
217 cases, 52.6%) and the lowest incidence in Oceania
(2438 cases, 0.82%). There were 9,555,027 cases of
deaths attributable to global cancers in 2018, of which
241,037 (2.71%) belonged to brain cancers. The highest
mortality rate was observed in Asia with 129,483 cases
(57.3%) and the lowest mortality in Oceania with 2017
cases (0.84%) (Fig. 1, [29, 30]).
According to the results, the highest incidence of brain
cancer was observed in Latvia (10.1 per 100,000), the
former Yugoslav Republic of Macedonia (9.2 per 100,
Fig. 1 Pie charts present the distribution of brain cancer’s cases and deaths by continent in 2018 for both sexes and all ages. [Source: GLOBOCAN 2018]
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000) and Lithuania (8 per 100,000), and the highest mor-
tality rates in the former Yugoslav Republic of Macedonia
(6.9 per 100,000), Armenia (6.1 per 100,000) and Albania
(5.8 per 100,000), respectively (Fig. 2, [29, 30]).
The analysis of variance revealed that the highest
mean incidence (5.08 per 100,000) was related to very
high HDI and the lowest (0.9 per 100,000) to low HDI
regions and this difference was statistically significant
(P < 0.0001). The lowest mortality rate (0.9 per 100,000)
was related to low HDI and the highest mortality rate
(3.6 per 100,000) to very high HDI regions. This difference
was also statistically significant (P < 0.0001) (Table 1).
The results suggested that incidence (r = 0.690, P <
0.0001) and mortality (r = 0.629, P < 0.001) of brain cancer
were significantly correlated with HDI (Fig. 3).
Moreover, as shown by the results, there was a positive
correlation between the incidence of brain cancer and
(r = 0.346, P < 0.001), MYS (r = 0.64, P < 0.001), LEB (r =
0.66, P < 0.001) and EYS (r = 0.667). Results also mani-
fested a significant positive correlation between mortality
rate and GNI (r = 0.28, P < 0.01), MYS (r = 0.591, P < 0.01),
LEB (r = 0.624, P < 0.01) and EYS (r = 0.605, P < 0.01)
(Table 2).
Discussion
The findings of this study demonstrated that the highest
incidence of brain cancer in the World belonged to
Latvia in continental Europe (10.1 per 100,000) and the
highest mortality rate was related to the Former Yugo-
slav Republic of Macedonia (6.9 per 100,000) and
Armenia, respectively. (6.1 per 100,000). In general, the
highest incidence of brain cancer was reported in Asia
(52.26%), followed by Europe (21.8%), Latin America
(10%), North America (9.1%), Africa (5.7%) and Oceania
Fig. 2 The map presenting a incidence and b mortality rates of brain cancer in both sexes and for all ages in in 2018. [Source: GLOBOCAN 2018]
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(0.87%). The difference in cancer incidence in these
areas can be attributed to disparity in the socioeconomic
status. HDI is a composite indicator that assesses human
development in the countries. The index demonstrates a
country’s status in three essential aspects of develop-
ment, including life expectancy, education, and decent
standards of living. Life expectancy is measured by the
average period that a person is expected to live. Education
is assessed based on years of potential education, and stan-
dards of living are measured based on per capita income
or gross domestic product (GDP). In countries with high
levels of HDI, the incidence and mortality of brain cancer
are higher. This could be attributed to early screening, ac-
curate healthcare services, early-stage diagnosis of disease,
and a precise registry system in these countries [31].
The highest incidence of brain cancer has been
observed in Australia, North America and Northern
Europe in both sexes [18]. The highest mortality rates
have been reported in China, the United States, India,
Brazil and Russia [32]. The incidence and mortality rates
of brain cancer has dropped in Western countries, but
they are still on rise in some developing countries in
Europe and Asia [33]. In European countries, the highest
incidence rate was reported in England, Ireland and
Northern Europe and the lowest in Eastern Europe [34].
Khodamoradi et al. (2017) reported that the highest
incidence and standardized mortality rate of brain
cancer belonged to Albania and there was a
significant positive correlation between HDI (income
level) and brain cancer incidence [15]. In the study of
Davis et al. on patients with malignant brain tumor, 2
and 5-year survival rate were 36.2 and 27.6% respect-
ively, which reflects a high mortality rate in low-
income countries. This study manifested a significant
positive correlation between HDI and brain cancer
[35].
A 2016 study by Miranda et al. showed a significant
positive association between HDI components and brain
cancer (P < 0.001). Brain tumor incidence was lower in
low-income individuals [36]. The findings of this study
are consistent with results of our study. The above stud-
ies suggest that cancer is still a major global health issue
in communities and more extensive studies are required
to investigate the link between economic development
and brain cancer.
Socioeconomic developments have been significantly
associated with the incidence and attenuation of cancer.
In low- and middle-income economies, the risk of can-
cers is on rise. Infections, as the leading cause of can-
cers, account for about 26% of cancers in middle- and
low-income countries. Increased life expectancy, aging,
lifestyle changes and exposure to biological hazards are
risk factors for brain cancer [15]. Brain cancer is associ-
ated with industrialization in societies, and global health
statistics suggest that most of cancer-induced deaths
occur in developing countries.
Table 1 Pearson correlation between HDI components and the dependent variable
HDI Incidence Rate Mortality Rate
CR ASR CR ASR
Very high human development 7.6 5.08 6.06 3.6
High human development 4.4 3.7 3.6 2.9
Medium human development 2.04 2.2 1.7 1.9
Low human development 0.7 0.9 0.6 0.9
P-value(F-test) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Abbreviations: CR Crude Rate, ASR Age-Standardized Rates per 100,000
Fig. 3 Correlation of HDI with incidence and mortality rates of brain cancer worldwide in 2018
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Our results also exhibited that HDI was significantly
correlated with the incidence (R = 0.690, P < 0.0001) and
mortality of brain cancer (R = 0.629, P < 0.001) in 2018.
The higher incidence of brain cancer in countries with
higher HDIs could be ascribed to appropriate infrastruc-
ture, advanced diagnostic techniques, convenient access
to primary healthcare, high quality of life, and early
screening. Important risk factors for cancers in most
countries are occupational and environmental hazards,
ionizing radiation, and radioactive radiation. Early pre-
vention strategies for brain cancer, such as diminished
exposure to occupational hazards in the workplace and
magnetic field exposure, can be effective in lowering the
risk of cancers. However, considering the association
between risk factors and outcomes, the results should be
interpreted with caution, because besides the epidemio-
logic risk factors, the inherent limitations of ecological
studies must also be taken into account. As the inci-
dence and mortality of brain cancer are on rise in many
countries, early preventive strategies, timely treatment,
and patients’ follow-up, especially in less- developed
countries, can help mitigate the disease burden and im-
prove the health of people in these countries.
Conclusion
According to the results of present study, the incidence
and mortality rates for brain cancer are higher in countries
with a higher HDI. The higher incidence rate in countries
with a higher HDI can be explained in terms of environ-
mental pollutants and occupational exposures to ionizing
radiation and industrial radioactive sources in these coun-
tries. On the other hand, it could be argued that the
higher rate of cancer in these countries may be due to
more advanced facilities that can diagnose the disease.
Therefore, further epidemiological studies about the fac-
tors related to the incidence and mortality of this disease
can be effective in reducing its incidence and mortality
rates.
Strengths and limitations of the study
Since the cancer information registration system in all
countries of the world is not collected with the same de-
gree of accuracy, so the incidence data in each country
may be affected by the information system of that
country and the accuracy of the incidence and mortality
rate in each country can be different.
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